SMS Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Los beneficios de SMS Pharmaceuticals han disminuido a una tasa media anual de -13.8%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 14.8% anualmente. Los ingresos han ido creciendo a una tasa media de 5.5% al año. La rentabilidad financiera de SMS Pharmaceuticals es de 7.5%, y sus márgenes netos son de 5.9%.
Información clave
-13.8%
Tasa de crecimiento de los beneficios
-13.8%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 17.5% |
Tasa de crecimiento de los ingresos | 5.5% |
Rentabilidad financiera | 7.5% |
Margen neto | 5.9% |
Próxima actualización de resultados | 29 May 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It
Oct 28What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?
Oct 08Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?
Sep 17SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Aug 26SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Could Signal Some Risk
Aug 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Business Is Trailing The Market But Its Shares Aren't
Aug 08SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Looks Just Right
Jul 25SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Matching Investor Opinion
Jul 07Desglose de ingresos y gastos
Cómo gana y gasta dinero SMS Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Dec 23 | 6,129 | 361 | 615 | 0 |
30 Sep 23 | 6,002 | 288 | 598 | 0 |
30 Jun 23 | 5,930 | 150 | 571 | 0 |
31 Mar 23 | 5,221 | -71 | 560 | 0 |
31 Dec 22 | 4,335 | -42 | 535 | 0 |
30 Sep 22 | 4,060 | 9 | 532 | 0 |
30 Jun 22 | 4,211 | 259 | 517 | 0 |
31 Mar 22 | 5,199 | 622 | 515 | 0 |
31 Dec 21 | 6,348 | 789 | 499 | 0 |
30 Sep 21 | 6,612 | 911 | 475 | 0 |
30 Jun 21 | 6,172 | 791 | 442 | 0 |
31 Mar 21 | 5,632 | 625 | 415 | 0 |
31 Dec 20 | 4,911 | 458 | 405 | 0 |
30 Sep 20 | 4,226 | 319 | 398 | 0 |
30 Jun 20 | 4,130 | 308 | 386 | 0 |
31 Mar 20 | 4,143 | 316 | 410 | 0 |
31 Dec 19 | 4,206 | 386 | 398 | 0 |
30 Sep 19 | 4,412 | 405 | 389 | 0 |
30 Jun 19 | 4,606 | 406 | 366 | 0 |
31 Mar 19 | 4,667 | 400 | 372 | 0 |
31 Mar 18 | 4,639 | 317 | 343 | 0 |
31 Mar 17 | 4,388 | 285 | 288 | 0 |
31 Mar 16 | 6,032 | 409 | 406 | 0 |
31 Dec 15 | 5,902 | 391 | 579 | 0 |
30 Sep 15 | 5,828 | 396 | 566 | 0 |
30 Jun 15 | 5,651 | 343 | 330 | 0 |
31 Mar 15 | 5,793 | 352 | 533 | 0 |
31 Dec 14 | 5,730 | 358 | 504 | 0 |
30 Sep 14 | 5,624 | 327 | 493 | 0 |
30 Jun 14 | 5,567 | 326 | 282 | 0 |
31 Mar 14 | 5,180 | 204 | 455 | 0 |
31 Dec 13 | 3,976 | 686 | 372 | 0 |
30 Sep 13 | 3,396 | 430 | 350 | 0 |
30 Jun 13 | 2,771 | -792 | 187 | 0 |
Ingresos de calidad: SMSPHARMA tiene ganancias de alta calidad.
Margen de beneficios creciente: SMSPHARMA pasó a ser rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de SMSPHARMA han disminuido en un 13.8% al año en los últimos 5 años.
Acelerando crecimiento: SMSPHARMA ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.
Beneficios vs. Industria: SMSPHARMA ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (23.8%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de SMSPHARMA (7.5%) se considera baja.